PMID: 8950332Jan 1, 1997Paper

Differences in dose scheduling as a factor in the etiology of anthracycline-induced cardiotoxicity in Ewing sarcoma patients

Medical and Pediatric Oncology
A P KakadekarR Popov

Abstract

Clinical observation suggested a high prevalence of cardiac morbidity and mortality in children with Ewing sarcoma (ES) treated at B.C.'s Children's Hospital. We therefore compared 30 patients treated for Ewing sarcoma between 1978 and 1991 with 26 soft tissue sarcoma (STS) patients treated with similar chemotherapy over the same period of time. All patients were evaluated for cardiac function using echocardiography. Shortening fraction (SF) and left ventricular mass index (Massl) were compared before and after treatment. The role of chest irradiation, dose concentration (DC) of adriamycin (AD), total mean doses of AD, cyclophosphamide (CY) and actinomycin (AC) were analysed. SF for patients with ES and STS postchemotherapy was significantly lower (P < .001 and P = 0.0004, respectively) than pretreatment values. Postchemotherapy SF for ES was lower than STS (P = 0.0097). Massl for each group did not change significantly. Six of the ES patients had postchemotherapy SF of < 0.20, with three in congestive failure, two cardiac deaths and one heart transplant. One additional ES patient had sick sinus syndrome and needed a pacemaker. Among the STS patients only one had SF < .20 and none were symptomatic. There were no significant dif...Continue Reading

References

Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Apr 1, 1977·Cancer·R A MinowJ A Gottlieb
Feb 1, 1976·Cancer·A C GilladogaM L Murphy
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Nov 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR C Young
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Sep 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E O BurgertP Thomas
Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M Hryniuk, M Goodyear
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
Feb 1, 1974·Annals of Internal Medicine·R H Blum, S K Carter
May 1, 1983·Southern Medical Journal·M ObamaJ van Eys
Jan 1, 1981·Medical and Pediatric Oncology·L J SteinherzD R Miller
Jul 1, 1980·The Journal of Pediatrics·T BiancanielloS Kaplan
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W CristR Heyn
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L HancockR T Hoppe
Jan 1, 1993·Medical and Pediatric Oncology·J H SilberG Barber
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R I JakackiJ H Silber

❮ Previous
Next ❯

Citations

Oct 16, 1999·British Journal of Haematology·G Levitt
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C M KremerP A Voûte
Feb 27, 2004·British Journal of Haematology·G A LevittI Sullivan
Feb 6, 2013·Pediatric Blood & Cancer·Tanya Renae BrownChristopher Fryer
Jan 16, 1999·Pediatric Clinics of North America·M Grossi
Dec 8, 2005·Pediatric Blood & Cancer·M PaulidesUNKNOWN German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH)
Dec 10, 2008·Pediatric Hematology and Oncology·Mehmet KantarSavas Kansoy
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.